natgillin/translations-raw huggingface dataset:
In another embodiment the invention is a pharmaceutical composition for use according to statement 17, characterized in that said tumor diseases are solid tumors, preferably epithelial tumors, such as prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, such as colon carcinoma; kidney cancer; thyroid carcinoma; uterine carcinoma; adrenal carcinoma. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 17 ili 18, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poput karcinoma prostate; karcinoma dojke; karcinoma gušterače; karcinoma pluća; karcinoma gastrointestinalnog sustava, poput karcinoma debelog crijeva; raka bubrega; karcinoma štitnjače; karcinoma maternice; karcinoma nadbubrežne žlijezde.
(1): A pharmaceutical composition consisting of: 0.02 percent by weight mechlorethamine hydrochloride; 2.00 percent by weight hydroxypropyl cellulose; 0.01 percent by weight edetate disodium dihydrate; 0.05 percent by weight racemic menthol; 0.01 percent by weight butylated hydroxytoluene; 49.91 percent by weight 2-(2-ethoxyethoxy)ethanol; 15.27 percent by weight isopropyl alcohol; 17.57 percent by weight propylene glycol; 11.33 percent by weight glycerin; 3.65 percent by weight racemic lactic acid; and 0.18 percent by weight sodium chloride; or a composition having the ingredients as above recited, for use as a medicament. 
HR P20190551 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak koji se sastoji od: 0.02 težinskih postotaka mekloretamin hidroklorida; 2.00 težinskih postotaka hidroksipropil celuloze; 0.01 težinskih postotaka dinatrijevog edetat dihidrata; 0.05 težinskih postotaka racemičnog mentola; 0.01 težinskih postotaka butiliranog hidroksitoulena; 49.91 težinskih postotaka 2-(2-etoksi-etoksijetanola; 15.27 težinskih postotaka izopropilnog alkohola; 17.57 težinskih postotaka propilen glikola; 11.33 težinskih postotaka glicerina; 3.65 težinskih postotaka racemične mliječne kiseline; i 0.18 težinskih postotaka natrijevog klorida.
Preferred sulfur compound that partly deactivates the hydrogenation catalyst is dimethyl sulfoxide, preferably in an amount of 0.18 to 0.33 mol, more preferably in an amount of 0.23 to 0.28 mol, per 1 mol of 7-ethylcamptothecin. 
Poželjni sumporni spoj koji djelomično deaktivira hidrogenacijski katalizator je dimetil-sulfoksid, po mogućnosti u količini od 0,18 do 0,33 mol, poželjnije u količini od 0,23 do 0.28 mol, na 1 mol 7-etilkamptotecina.
substituted or unsubstituted alkyl; 
supstituirani ili nesupstituirani alkil;
In addition to the foregoing, the compounds of formulae (I) and (Ia) are also indicated for use in the therapy of septic shock, e.g., as anti-hypovolaemic and/or anti-hypotensive agents; in the treatment of inflammatory bowel disease; cerebral oedema; headache; migraine; inflammatory skin disease, such as eczema and psoriasis; inflammatory disorders of the gut, e.g., irritable bowel syndrome; Crohn's disease; ulcerative colitis; and cystitis, e.g., interstitial cystitis, nephritis and uveitis. 
Dodatno uz gore navedeno, spojevi formula (I) i (Ia) mogu se također propisati za upotrebu u terapiji septičkog šoka, npr. kao anti-hipovolemiska 1/ili anti-hipotenzivna sredstva; u liječenju upalne bolesti crijeva; cerebralnog edema; glavobolje; migrene; upalne kožne bolesti, kao što su ekcem i psorijaza; upalni poremećaji crijeva, npr. sindrom nadražcnih crijeva; Crohnova bolcst; ulecrativni kolitis; 1 cistitis, npr. intersticijalni cistitis, nefritis i uvcitis.
The process of any one of claims 1 to 11 and 15 to 22, wherein the curing step c) takes place in a bed of free flowing extended release matrix formulations. 
Postupak prema bilo kojem zahtjevu od 1 do 11 1 od 15 do 22, naznačen time da se korak stvrdnjavanja odvija u sloju formulacija matrice s produljenim otpuštanjem koje se slobodno kreću.
ST2472 was metabolically more stable than ST1899: the main metabolite obtained was M3 (FIG. 4). 
ST2472 bio je metabolički stabilniji od ST1899: glavni dobiveni metabolit bio je M3 (Slika 4).
The method of claim 27, wherein the constant region of an immunoglobulin is an Fc domain. 
Fuzijski polipeptid za uporabu prema zahtjevu 16, pri čemu je konstantna regija imunoglobulina Fc domena.
The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. 
Za terapeutske ili profilaktičke potrebe, razina doze spoja prikazanog Formulom I će, naravno, varirati o težini zdravstvenog stanja, dobi i spolu životinje ili pacijenta i načinu davanja, u skladu sa dobro poznatim medicinskim principima.
Also described herein are the following items: A method for reducing IL-6 and/or VCAM-1 in a subject comprising administering to the subject in need thereof, a therapeutically effective amount of at least one compound of Formula I: 
PATENTNI ZAHTJEVI 1. = Farmaceutski sastav, naznačen time, da se upotrebljava u smanjivanju IL-6 za liječenje raka kod pojedinca, pri čemu sastav obuhvaća terapeutski učinkovitu količinu najmanje jednog spoja formule I:
X- is a physiologically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. 
X- je fiziološki prihvatljiv anion kojeg se bira iz skupine koju čme klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat i p-toluensulfonat.
Caramel is usually a dark brown to black liquid or solid having an odour of burnt sugar and a somewhat bitter taste. 
Karamela je obično tamno smeđa do crna tekućina ili krutina koja ima miris spaljenog šećera i pomalo gorak okus.
The topical veterinary composition of paragraph 10, wherein the at least second active agent is an insect growth regulator, a neonicotinoid or an avermectin or milbemycin. 
Topikalni veterinarski pripravak prema zahtjevu 7, naznačen time, da je najmanje druga djelatna tvar regulator rasta kukaca, neonikotinoid ili avermektin ili milbemicin.
The maleate salt of claim 2, wherein at least 99% by weight of the maleate salt is single crystalline form A. 
Maleat sol sukladno patentnom zahtjevu 12 ili 13, pri čemu je najmanje 99% težine soli u jednom kristalnom obliku.
The solution was filled into 25 ml glass vials at 5 ml/vial and maintained at −20° C. until lyophilization process. 
Otopina je napunjena u 25 ml staklene ampule u količini od 5 ml/ampuli i održavana na - 20%C€ do procesa liofilizacije.
The ferric chloride is preferably present in the mixture in a catalytic amount, preferably 25000 ppm or lower, for example 5000 ppm, 2000 ppm, or 1000 ppm or lower. 
Postupak iz patentnog zahtjeva 1, pri čemu je željezov(IlI) klorid prisutan u reakcijskoj smjesi u količini koja je u rasponu od 30 do 1000 ppm.
In other embodiments, the pharmaceutical composition of the present invention comprises at least about 0.1% by weight of the API, alternatively—at least 0.5% by weight of the API. 
Farmaceutski pripravak prema patentnom zahtjevu 1, koji sadrži najmanje 0,01 %, najmanje 0,1 % ili najmanje 0,5 % masenog udjela djelatnog farmaceutskog sastojka (API).
A process according to claim 5 wherein the compound of formula VI in step d) is isolated in its monoacetate salt form. 
Postupak u skladu sa zahtjevom 11, naznačen time, da se spoj formule VI u koraku d) izolira u obliku svoje 10
The anti-sclerostin antibody for use in the method of claim 1, wherein the method further comprises administering a second bone-enhancing therapeutic selected from the group consisting of parathyroid hormone, a bisphosphonate, a RANKL antibody and a DKK-1 antibody. 
Antisklerostinsko antitijelo za primjenu u načinu prema zahtjevu 1, naznačeno time, što se način dodatno sastoji od primjene drugog terapijskog sredstva za jačanje kosti odabranog iz skupine koja se sastoji od paratiroidnog hormona, bisfosfonata, RANKL antitijela i DKK-1 antitijela.
a monoacid lipid A (MALA) adjuvant; and a pharmaceutically acceptable carrier. 
(b) -monokiselinski lipid A (MALA) adjuvans; i (c) farmaceutski prihvatljivi nosač.
The composition according to the invention is preferably in form of a coated or uncoated tablet, e.g. fast disintegrating tablet or orally disintegrating tablet, a capsule or in the form of pellets. 
Poželjno je da je pripravak prema ovom izumu u obliku obložene ili neobložene tablete, primjerice brzo raspadajuće tablete ili tablete koja se raspada u ustima, kapsule ili u obliku peleta.
-Bromomethyl-4-nitro-benzoic acid ethyl ester (3.4 mmol) (Can be prepared according to literature procedures: Damen et al.; Bioorg.Med.Chem.; EN; 10; 1; 2002; 71 - 78) was suspended in MeOH (20 mL). 
Etilni ester 3-bromometil-4-nitro benzojeve kiseline (3.4 mmol) (može se priprediti prema podacima koji postoje u literaturi: Damen et al.; Bioorg. Med. Chem.; EN; 10; 1; 2002; 71-78) se suspendira u MeOH (20 ml).
The composition or vaccine for use according to any one of claims 4-7, wherein the animal is avian. 
Sastav, cjepivo ili vektor za uporabu prema bilo kojem od zahtjeva 1 do 9 ili 11 do 13, naznačeni time, da životinja je ptica.
an isotropic blurring device (14) configured to apply an isotropic smoothing filter to the original image (P0) to generate an isotropic blur image (P1); 
(C) uređaj za izotropno zamagljenje (14) koji ima konfiguraciju za nanošenje izotropnog filtera za omekšavanje šuma na originalnu sliku (PO) u svrhu stvaranja izotropne zamagljene slike (P1);
The pharmaceutical composition for use of claim 23, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, chronic bronchitis, emphysema, bronchiectasis, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija za uporabu prema patentnom zahtjevu 30, naznačena time što se bolest ili stanje bira od astme, KOPB, pogoršanja hiper reaktivnosti dišnih putova kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, sindroma respiratornog distresa, plućne hipertenzije, i upale pluća i opstrukcije povezane s cističnom fibrozom.
The apparatus according to claim 1, wherein the predefined time is from 1 to about 5 seconds. 
Uređaj sukladno Zahtjevu 4 ili 5 pri čemu je navedeno predefinirano vrijeme 1 do 5 sekundi.
A binding molecule according to claim 1 or 2, wherein the binding molecule is an IgG. 
Molekula za vezanje u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je molekula za vezanje IgG.
Purification on a silica gel column (hexane: ethyl acetate, 4:1) afforded 10.0g (98%) of title compound as white foam. 
Pročišćavanje na koloni silikagela (heksan:etil-acetat 4:1) daje 10,0 g (98%) spoja iz naslova kao bijelu pjenu.
A composition comprising a bacterial strain of the species Roseburia hominis, for use in a method of treating or preventing asthma. 
PATENTNI ZAHTJEVI Sastav koji obuhvaća bakterijski soj vrste Roseburia hominis, za upotrebu u postupku liječenja ili prevencije astme.
the hyaluronidase is administered prior to administration of the IG; the IG composition has a protein concentration that is 5 to 25% w/v IG; 
koncentracija IG je 5 do 15% m/v i količina IG u pripravku je 0.5 grama (g) do 70 g;
The apparatus according to claim 12, adapted such that the contact of the off-gas with the oxidation catalyst is controlled based on the oxygen content of the exhaust gas measured by the oxygen monitor such that the oxygen content of the off-gas after the contact with the oxidation catalyst is within the range of 1-16%. 
Uređaj prema zahtjevu 13 ili zahtjevu 14, prilagođen tako da se kontakt s oksidacijskim katalizatorom kontrolira putem monitora kisika tako da se sadržaj kisika u oslobođenom plinu nakon kontakta s oksidacijskim katalizatorom kreće u rasponu od 1-16%.
The method according to claim 1, wherein the composition is administered separately, as a coadjuvant or an auxiliary drug, from at least another drug effective for the treatment of schizophrenia. 
Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje odvojeno, kao suadjuvans ili pomoćni lijek, od najmanje još jednog lijeka djelotvornog u sprječavanju i/ili liječenju psihijatrijskih poremećaja CNS-a.
An integral metal end cap according to claim 1 wherein the integral body comprises metal having a thickness from and including 1 mm to and including 5 mm. 
Integrirani metalni poklopac u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da integralno tijelo ima debljinu od 1 do 5 mm.
A pharmaceutical composition, which contains deuterated catecholamines according to one of claims 1 to 3 as well as physiologically acceptable salts thereof, for the treatment of Parkinson's disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, in addition to pharmaceutically acceptable adjuvants and additives. 
L-2-Amino-2,3-dideutero-3-(3,4-dihidroksifenil) propionska kiselina i stereoizomeri, enantiomeri ili diastereomeri u optički čistom obliku kao i njihove fiziološki prihvatljive soli naznačeni time da su za liječenje Parkinsonove bolesti, sindroma nemirnih nogu, distonije, za inhibiranje izlučivanja prolaktina, za stimuliranje oslobađanja hormona rasta, za liječenje neuroloških simptoma kroničnih intoksikacija manganom, amiotrofične lateralne skleroze i multiple sistemske atrofije.
disinfecting said untreated sewage water by carrying out the following steps: 
dezinfekcije navedeno nepročišćene otpadne vode putem provođenja sljedećih koraka:
represents [1]a hydrogen atom, [2] a cyano group, or [3] a halogen atom; R 2 is selected from the group consisting of: 
R' predstavlja [1] atom vodika, [2] skupina cijano ili [3] atom halogena; R/ se bira iz skupine koju čine:
Use of a cyclosporin in the preparation of a pharmaceutical composition for preventing or treating Hepatitis C infections or HCV induced disorders. wherein the cyclosporine (i) binds to human recombinant cyclophilin with a binding ratio (BR) of less than 0.7, BR being the log to base 10 of the ratio of the IC50 of the cyclosporine to the IC50 of cyclosporin A as measured in a competitive ELISA test; and (ii) has an activity in the Mixed Lymphocyte Reaction of not more than 5% that of cyclosporin A, wherein the cyclosporin is a compound of formula la in which 
PATENTNI ZAHTJEVI L Uporaba ciklosporina, naznačena time, da se koristi za pripravu farmaceutskog pripravka za prevenciju ili liječenje infenkcije Hepatitis € ili HCV induciranih poremećaja, pri čemu se ciklosporin (i) veže na humani rekombinantni ciklofilin s vezujućim omjerom (binding ratio BR) manjim od 0.7, gdje BR je log baze 10 omjera IC5, ciklosporina prema ICs9 ciklosporina A izmjereno u kompetitivnom ELISA testu; te (ii) ima aktivnost u miješanoj limfocitnoj reakciji (Mixed Lymphocyte Reaction) ne veću od 5% ciklosporina A, gdje je ciklosporin spoj formule Ia
prior to step (vi): stacking said board-like pieces of wood (12). 
(vii)prije faze (vi): slaganje navedenih komada od drva koji imaju oblik grede (12).
The following methods may be applied for the preparation of these salts. 
Slijedeći postupci mogu se primijeniti za pripravljanje tih soli.
The sterile composition according to claim 1, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, and mixtures thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter. (BDDE), 1,4-bis(2,3- epoksipropoksi)butan, = 1,4-bisglicidiloksibutan, = 1,2-bis(2,3-epoksipropoksijetilen, - 1-(2,3-epoksipropil)-2,3- epoksicikloheksan, pustrescin, spermidin, spermin, te njihovu smjesu.
The following Preparations illustrate the preparation of certain starting materials. 
Slijedeći preparati ilustriraju dobi janje izvjesnih polaznih materi jala.
Synthesis of Compounds of the Invention: 
Datum podnošenja europske prijave patenta:
Tablets containing donepezil hydrochloride hydrate were stored for 30 days at a temperature of 50°C. Tablets were not packaged in a contact packing material such as blisters. 
Tablete koje sadrže donepezil hidroklorid hidrat skladištene su tijekom 30 dana na temperaturi od 50 *C. Tablete nisu bile pakirane u kontaktu sa materijalom za pakiranje, kao što su primjerice blisteri.
An antisense oligonucleotide containing 20-35 morpholino subunits linked by phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, comprising a base sequence of SEQ ID NO: 382, or a sequence having at least 80% sequence identity thereto, in which thymine bases are optionally uracil bases, and wherein the antisense oligonucleotide is complementary to human dystrophin pre-mRNA to induce exon 52 skipping; or a pharmaceutically acceptable salt thereof. 
HR P20190387 T1 PATENTNI ZAHTJEVI Protusmisleni oligonukleotid koji sadrži 20-35 morfolino podjedinica povezanih s vezama među podjedinicama koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice sa 5' 'egzocikličkim ugljikom susjedne podjedinice, koji sadrži baznu sekvencu SEQ ID NO: 382, ili sekvencu koja ima s njom barem 80% identičnosti sekvence, pri čemu su timinske baze proizvoljno uracilne baze, te pri čemu je protusmisleni oligonukleotid komplementaran s ljudskim distrofinom pred-mRNA da se inducira preskakanje eksona 52; ili njegova farmaceutski prihvatljiva sol.
(b1) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 108, 109, and 110 (H chain CDRs of J232), respectively; 
(bl) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 21 3 od SEQ ID NO: 108, 109 odnosno 110 (H-lanac CDR-područja od J232);
at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000 and 7,000,000; and 
najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, molekularnu težinu od najmanje 1,000,000; te
The antibody or antigen binding fragment thereof or composition or pharmaceutical composition for use as defined in claim 18, wherein the cancer is selected from the group consisting of ovarian cancer, skin cancer, renal cancer, colorectal cancer, sarcoma, leukemia, brain cancer, thyroid cancer, breast cancer, prostate cancer, oesophageal cancer, bladder cancer, lung cancer and head and neck cancer and/or wherein the cancer is metastatic. 
Humanizirano protutijelo ili njegov fragment koji veže antigen ili pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak jajnika, rak kože, rak bubrega, kolorektalni rak, sarkom, leukemija, rak mozga, rak tiroidne žlijezde, rak dojke, rak prostate, rak jednjaka, rak mjehura, rak pluća 1 rak glave 1 vrata i/ili time, da je rak metastatski.
The method according to claim 1, wherein the fluid pressure acts on the sealing material such that the sealing material is pressed both against the enclosure member and the outer surface of the capsule. 
Postupak u skladu s patentnim zahtjevom 1, u kojemu fluid pod tlakom djeluje na materijal za brtvljenje (8) na takav način da se materijal za brtvljenje potisne i prema elementu za obuhvaćanje i prema vanjskoj površini čahure
expanding the isolated DPFs in monolayer culture without collagen coating, wherein said DPFs are passaged at least once, and 
(c) ekspandiranja izoliranih DPF-ova u jednoslojnoj kulturi bez kolagenske prevlake, pri čemu su navedeni DPF- ovi barem jednom pomaknuti,
A recombinant vector comprising operatively linked in the 5' to 3' direction: a promoter which functions in a host cell; a structural nucleic acid sequence of any of aspects 9-15 wherein said nucleic acid sequence encodes a lectin protein; and a termination signal. 
Rekombinantni vektor koji sadrži operativno povezane u smjeru 5* do 3': promotora koji funkcionira u stanici domaćinu; strukturalni slijed nukleinske kiseline kako je definirana u patentnom zahtjevu 5 ili 6, naznačene time da navedeni slijed nukleinske kiseline kodira bjelančevinu tipa lektina; te signal za završetak.
measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound; and 
mjerenje aktivnosti navedenog CFTR ili njegovog fragmenta u prisutnosti dodatnog spoja i
Soft elastic and hard-filled gelatin capsules containing this pharmaceutical composition are then prepared, employing a sufficient quantity of material in each instance so as to provide each capsule with 50 mg. of the active ingredient. 
Tada se naprave meke elastične 1 tvrde želatinske kapsule koje sadrže farmaceutski preparal, korištenjem zadovoljavajuće količine materijala u svakom slučaju tako da se svaka kapsula osigura sa 50 mg aktivnog sastojka.
A compound represented by the structure of formula VI: wherein R1', R3', R4', R6' R7', and R9' are the same and selected from heterocycloalkyl, alkoxy and dialkylamino, and R10 is methyl; 
vV u kojoj je R; metil grupa, a Ry, R», Ra', Ry' Rs', i R4! iste ili različite grupe izabrane od dialkilamino, N-piperidin, N-pirolidin, N-piperazin, N-piperazine-4-metil i N-morfolin. 2. Spoj iz zahtjeva 1, okarakteriziran formulom VI:
The variations disclose the box and its blank with the edges creased 27, whereat the creased edges 27 may form either orbiculations or obliquity of said edges. 
Varijante otkrivaju kutiju i njenu shemu sa presavijenim rubovima 27, gdje presavijeni rubovi 27 mogu biti bilo zaobljeni bilo kosi.
reduction of LDL-C of at least -60 % to at least -75% relative to a predose level with a sustained reduction over at least a 14 day-period upon administering to a subject a dose of 150 mg E2W; 
(a) smanjenje LDL-C od barem -60% do barem -75% u odnosu na razinu prije doziranja uz održivo smanjenje tijekom najmanje 14 dana nakon davanja subjektu doze od 150 mg E2W;
Example 10. A device according to example 9, wherein the interior passage is a part of said first interior guiding passage (10). 
Uredaj u skladu s patentnim zahtjevom 10, kod kojega je unutarnji prolaz dio navedenog prvog unutarnjeg prolaza za vođenje (10).
The method of any one of embodiments 1 to 5, wherein the level of C1-INH that binds to the capture agent is measured by an enzyme-linked immunosorbent assay (ELISA). 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time što se razina funkcionalnog C1-INH koja se veže na sredstvo za hvatanje mjeri pomoću enzimski vezanog imunoapsorbirajućeg testa (ELISA).
A nucleic acid comprising a nucleotide sequence encoding the peptide of claim 1 or 2, wherein the nucleic acid is preferably a recombinant nucleic acid. 
Nukleinska kiselina koja sadrži nukleotidnu sekvencu koja kodira peptid sukladno patentnom zahtjevu 1 ili 2, naznačena time, da je nukleinska kiselina, poželjno, rekombinantna nukleinska kiselina.